420 G.A. Cabral and A. Staab
Luo YD, Patel MK, Wiederhold MD, Ou DW (1992) Effects of cannabinoids and cocaine on
the mitogen-induced transformations of lymphocytes of human and mouse origins. Int
J Immunopharmacol 14:49–56
Luthra YK, Esber HJ, Lariviere DM, Rosenkrantz H (1980) Assessment of tolerance to im-
munosuppressive activity of delta-9-tetrahydrocannabinol in rats. J Immunopharmacol
2:245–256
Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989) Delta-9-tetrahydro-
cannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neu-
roimmunol 23:73–81
Lynn AB, Herkenham M (1994) Localization of cannabinoid receptors and nonsaturable
high-density cannabinoid binding sites in peripheral tissues of the rat: implications
for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther
268:1612–1623
Marciano-Cabral F (1988) Biology of Naegleria spp. Microbiol Rev 52:114–133
Marciano-Cabral F, Ferguson T, Bradley SG, Cabral G (2001) Delta-9-tetrahydrocannabinol
(THC), the major psychoactive component of marijuana, exacerbates brain infection by
Acanthamoeba. J Eukaryot Microbiol Suppl:4S–5S
Massi P, Fuzio D, Vigano D, Sacerdote P, Parolaro D (2000) Relative involvement of cannabi-
noid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibi-
tion of natural killer activity. Eur J Pharmacol 387:343–347
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabi-
noid receptor and functional expression of the cloned cDNA. Nature 346:561–564
McCoy KL, Gainey D, Cabral GA (1995) Delta-9-tetrahydrocannabinol modulates antigen
processing by macrophages. J Pharmacol Exp Ther 273:1216–1223
McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA (1999) Cannabinoid inhibition of the
processing of intact lysozyme by macrophages: evidence for CB2 receptor participation.
J Pharmacol Exp Ther 289:1620–1625
McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS (2002) Delta(9)-tetra-
hydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of im-
munosuppression in vitro and in vivo. J Pharmacol Exp Ther 302:451–465
MechoulamR,BenShabatS,HanusL,LigumskyM,KaminskiNE,SchatzAR,GopherA,
Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel
Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that
binds to cannabinoid receptors. Biochem Pharmacol 50:83–90
Meyers WA, III, Heath RG (1979) Cannabis sativa: ultrastructural changes in organelles of
neurons in brain septal region of monkeys. J Neurosci Res 4:9–17
Miller JM Jr, Goodridge C (2000) Antenatal marijuana use is unrelated to sexually transmit-
ted infections during pregnancy. Infect Dis Obstet Gynecol 8:155–157
Mishkin EM, Cabral GA (1985) Delta-9-tetrahydrocannabinol decreases host resistance to
herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 66:2539–
2549
Molina-Holgado F, Molina-Holgado E, Guaza C (1998) The endogenous cannabinoid anan-
damide potentiates interleukin-6 production by astrocytes infected with Theiler’s
murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 433:
139–142
Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE (1979) Effects of cannabinoids
on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun
23:670–674
Morahan PS, Morse SS, McGeorge MG (1980) Macrophage extrinsic antiviral activity during
herpes simplex virus infection. J Gen Virol 46:291–300
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral
receptor for cannabinoids. Nature 365:61–65
Nahas GG, Morishima A, Desoize B (1977) Effects of cannabinoids on macromolecular
synthesis and replication of cultured lymphocytes. Fed Proc 36:1748–1752